Ibandronate
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Menopausal Osteoporosis
Conditions
Post-Menopausal Osteoporosis
Trial Timeline
Dec 1, 2006 → Oct 1, 2008
NCT ID
NCT00545779About Ibandronate
Ibandronate is a phase 3 stage product being developed by Roche for Post-Menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00545779. Target conditions include Post-Menopausal Osteoporosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02561039 | Phase 3 | Completed |
| NCT00545779 | Phase 3 | Completed |
| NCT02553707 | Approved | Completed |
| NCT00545363 | Approved | Completed |
| NCT02716792 | Phase 3 | Completed |
| NCT02598453 | Approved | Completed |
| NCT02564107 | Approved | Completed |
| NCT02598934 | Approved | Completed |
| NCT02604836 | Approved | Completed |
Competing Products
19 competing products in Post-Menopausal Osteoporosis